What AEON Biopharma, Inc. does.

AEON is a biopharmaceutical company advancing its proprietary botulinum toxin complex ABP-450 as a biosimilar to Botox® (onabotulinumtoxinA) with the goal of achieving full-label United States (“U.S.”) market entry for debilitating medical conditions.

On December 12, 2022, AEON Biopharma Sub, Inc. (formerly known as AEON Biopharma, Inc.) (“Old AEON”) and Priveterra Merger Sub, Inc., a wholly owned subsidiary of Priveterra Acquisition Corp. (“Priveterra”), a special purpose acquisition company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or other similar business combination with one or more target businesses, entered into a Business Combination and Merger Agreement (the “Business Combination Agreement” or “BCA”) dated December 12, 2022 and amended April 27, 2023.

On July 21, 2023 (the “Closing Date”), the parties consummated the transactions contemplated by the BCA (collectively referred to as the “Merger” or “Business Combination”) in connection with the closing of the Merger (the “Closing”). On the Closing Date, Old AEON merged with Priveterra Merger Sub, Inc., with Old AEON surviving the merger as a wholly owned subsidiary of the Company; and the Company changed its name from “Priveterra Acquisition Corp.” to “AEON Biopharma, Inc.”; and Old AEON changed its name to AEON Biopharma Sub, Inc. The post-Merger Company is referred to herein as “AEON,” or the “Company.”

Revenue and profit, by fiscal year.

More on AEON.

• AEON Biopharma, Inc. summary
• AEON Biopharma, Inc. financial statements
• AEON Biopharma, Inc. key metrics
• AEON Biopharma, Inc. health scores and style box
• AEON Biopharma, Inc. earnings
• AEON Biopharma, Inc. dividends
• AEON Biopharma, Inc. valuation
• AEON Biopharma, Inc. ownership and insiders
• AEON Biopharma, Inc. peers

Figures from AEON Biopharma, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.